Sanofi Initiates Phase 2 Clinical Trial to Evaluate Parkinson's Therapy

Sanofi Genzyme, the specialty care global business unit of Sanofi, announced the start of a Phase 2 trial of an investigational oral therapy for patients with Parkinson's disease who carry a single copy of a gene mutation that is the most common genetic risk factor for the disease.

Saved in:
Bibliographic Details
Published inPharmaceutical Processing
Main Author Genzyme, Sanofi
Format Trade Publication Article
LanguageEnglish
Published Rockaway Advantage Business Media 14.02.2017
Subjects
Clinical trials
Genes
Mutation
Parkinsons disease
Online AccessGet full text

Cover

More Information
Summary:Sanofi Genzyme, the specialty care global business unit of Sanofi, announced the start of a Phase 2 trial of an investigational oral therapy for patients with Parkinson's disease who carry a single copy of a gene mutation that is the most common genetic risk factor for the disease.
ISSN:1049-9156